On August 31, 2021, ARS Pharmaceuticals, a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, announced that it closed a $55 million Series D financing. The round was led by SR One, with participation from RA Capital Management and one other U.S.-based, healthcare-focused fund, as well as existing investor Deerfield Management. ARS will use the funds to advance Neffy™—an epinephrine nasal spray—through approval, support initial launch activities, and evaluate Neffy in clinical studies for additional indications. Neffy could provide an easy-to-use, convenient, and more reliable treatment for severe allergic reactions to food, medications, and insect bites that could lead to life-threatening anaphylaxis. Wilson Sonsini Goodrich & Rosati advises ARS Pharmaceuticals on all IP matters and represented the company in IP matters related to the transaction.

“This additional funding will allow us to focus on pre-launch activities for Neffy and additional research and development for a second indication for nasal epinephrine that we believe can add significant value to the ARS portfolio. This investment advances further work to prepare for launch of a reliable, easy-to-use, needle-free option for the treatment of a severe allergic reaction," said Richard Lowenthal, founder, chief executive officer, and president of ARS Pharma.

The Wilson Sonsini patents and innovations team that advised ARS Pharmaceuticals on IP matters related to the transaction was led by Val Zunic and included Grant Margulieux and Mike Hostetler.

For more information, please see ARS Pharmaceuticals’ press release.